For children between the ages of 5 and 16 who have asthma that is not being controlled by a combination of a short-acting beta agonist (SABA) and a low-dose inhaled corticosteroid (ICS), it is recommended to add a leukotriene receptor antagonist to their asthma management plan.

Managing Asthma in Children: NICE Guidelines

Asthma management in children has been updated by NICE in 2017, following the 2016 BTS guidelines. The new guidelines for children aged 5-16 are similar to those for adults, with a stepwise approach for treatment. For newly-diagnosed asthma, short-acting beta agonist (SABA) is recommended. If symptoms persist, a combination of SABA and paediatric low-dose inhaled corticosteroid (ICS) is used. Leukotriene receptor antagonist (LTRA) is added if symptoms still persist, followed by long-acting beta agonist (LABA) if necessary. Maintenance and reliever therapy (MART) is used as a combination of ICS and LABA for daily maintenance therapy and symptom relief. For children under 5 years old, clinical judgement plays a greater role in diagnosis. The stepwise approach is similar to that for older children, with an 8-week trial of paediatric moderate-dose ICS before adding LTRA. If symptoms persist, referral to a paediatric asthma specialist is recommended.

It should be noted that NICE does not recommend changing treatment for well-controlled asthma patients simply to adhere to the latest guidelines. The definitions of low, moderate, and high-dose ICS have also changed, with different definitions for adults and children. For children, <= 200 micrograms budesonide or equivalent is considered a paediatric low dose, 200-400 micrograms is a moderate dose, and > 400 micrograms is a high dose. Overall, the new NICE guidelines provide a clear and concise approach to managing asthma in children.

The patient’s elevated CK levels and urine test indicating blood without cells strongly suggest rhabdomyolysis as the cause of their kidney failure, likely due to their fall and prolonged time on the floor. Treatment should focus on managing hyperkalemia and ensuring proper hydration. While acute myocardial infarction cannot be ruled out entirely, the absence of discolored urine and other symptoms make rhabdomyolysis a more likely diagnosis. Acute tubular necrosis is also unlikely, as there are no epithelial cells present on urinalysis. While sepsis should be considered, the presence of red-colored urine and a history of a fall make rhabdomyolysis the most probable cause. Polymyositis, a type of inflammatory myopathy, typically presents with proximal myopathy and is more commonly seen in middle-aged women.

Understanding Molluscum Contagiosum

Molluscum contagiosum is a viral skin infection that is commonly seen in children, particularly those with atopic eczema. It is caused by the molluscum contagiosum virus and can be transmitted through direct contact or contaminated surfaces. The infection presents as pinkish or pearly white papules with a central umbilication, which can appear anywhere on the body except for the palms of the hands and soles of the feet. In children, lesions are commonly seen on the trunk and in flexures, while in adults, sexual contact may lead to lesions developing on the genitalia, pubis, thighs, and lower abdomen.

While molluscum contagiosum is a self-limiting condition that usually resolves within 18 months, it is important to avoid sharing towels, clothing, and baths with uninfected individuals to prevent transmission. Scratching the lesions should also be avoided, and treatment may be considered if the itch is problematic. However, treatment is not usually recommended, and if necessary, simple trauma or cryotherapy may be used. In some cases, referral may be necessary, such as for individuals who are HIV-positive with extensive lesions or those with eyelid-margin or ocular lesions and associated red eye.

Overall, understanding molluscum contagiosum and taking appropriate precautions can help prevent transmission and alleviate symptoms.

If there is a sensorineural issue during Weber’s test, the sound will be perceived on the healthy side (right), suggesting a problem on the opposite side (left).

Rinne’s and Weber’s Test for Differentiating Conductive and Sensorineural Deafness

Rinne’s and Weber’s tests are two diagnostic tools used to differentiate between conductive and sensorineural deafness. Rinne’s test involves placing a tuning fork over the mastoid process until the sound is no longer heard, then repositioning it just over the external acoustic meatus. A positive test indicates that air conduction (AC) is better than bone conduction (BC), while a negative test suggests conductive deafness if BC is greater than AC.

On the other hand, Weber’s test involves placing a tuning fork in the middle of the forehead equidistant from the patient’s ears and asking which side is loudest. In unilateral sensorineural deafness, sound is localized to the unaffected side, while in unilateral conductive deafness, sound is localized to the affected side.

To interpret the results of Rinne’s and Weber’s tests, a normal result indicates that AC is greater than BC bilaterally, and the sound is midline in Weber’s test. Conductive hearing loss is indicated by BC being greater than AC in the affected ear, while AC is greater than BC in the unaffected ear, and the sound lateralizes to the affected ear in Weber’s test. Sensorineural hearing loss is indicated by AC being greater than BC bilaterally, and the sound lateralizes to the unaffected ear in Weber’s test.

In cases of refractory anaphylaxis where two doses of IM adrenaline have failed to improve the patient’s condition, the Resuscitation Council guidelines (2021) recommend seeking expert help for consideration of low-dose IV adrenaline infusion. Therefore, the correct answer is to seek expert help for IV adrenaline administration under guidance. Administering adenosine, setting up an adrenaline infusion without specialist help, waiting for 5 or 10 minutes before giving another dose of IM adrenaline are all incorrect options. It is important to follow the guidelines and seek expert help for appropriate management of refractory anaphylaxis.

Anaphylaxis is a severe and potentially life-threatening allergic reaction that affects the entire body. It can be caused by various triggers, including food, drugs, and insect venom. The symptoms of anaphylaxis typically occur suddenly and progress rapidly, affecting the airway, breathing, and circulation. Common signs include swelling of the throat and tongue, hoarse voice, respiratory wheeze, dyspnea, hypotension, and tachycardia. In addition, around 80-90% of patients experience skin and mucosal changes, such as generalized pruritus, erythematous rash, or urticaria.

The management of anaphylaxis requires prompt and decisive action, as it is a medical emergency. The Resuscitation Council guidelines recommend intramuscular adrenaline as the most important drug for treating anaphylaxis. The recommended doses of adrenaline vary depending on the patient’s age, ranging from 100-150 micrograms for infants under 6 months to 500 micrograms for adults and children over 12 years. Adrenaline can be repeated every 5 minutes if necessary, and the best site for injection is the anterolateral aspect of the middle third of the thigh. In cases of refractory anaphylaxis, IV fluids and expert help should be sought.

Following stabilisation, patients may be given non-sedating oral antihistamines to manage persisting skin symptoms. It is important to refer all patients with a new diagnosis of anaphylaxis to a specialist allergy clinic and provide them with an adrenaline injector as an interim measure before the specialist assessment. Patients should also be prescribed two adrenaline auto-injectors and trained on how to use them. A risk-stratified approach to discharge should be taken, as biphasic reactions can occur in up to 20% of patients. The Resus Council UK recommends a fast-track discharge for patients who have had a good response to a single dose of adrenaline and complete resolution of symptoms, while those who require two doses of IM adrenaline or have a history of biphasic reaction should be observed for at least 12 hours following symptom resolution.

It is recommended to increase the dose of metformin gradually, with a minimum of one week between each increase.

Metformin is a medication commonly used to treat type 2 diabetes mellitus. It belongs to a class of drugs called biguanides and works by activating the AMP-activated protein kinase (AMPK), which increases insulin sensitivity and reduces hepatic gluconeogenesis. Additionally, it may decrease the absorption of carbohydrates in the gastrointestinal tract. Unlike other diabetes medications, such as sulphonylureas, metformin does not cause hypoglycemia or weight gain, making it a first-line treatment option, especially for overweight patients. It is also used to treat polycystic ovarian syndrome and non-alcoholic fatty liver disease.

While metformin is generally well-tolerated, gastrointestinal side effects such as nausea, anorexia, and diarrhea are common and can be intolerable for some patients. Reduced absorption of vitamin B12 is also a potential side effect, although it rarely causes clinical problems. In rare cases, metformin can cause lactic acidosis, particularly in patients with severe liver disease or renal failure. However, it is important to note that lactic acidosis is now recognized as a rare side effect of metformin.

There are several contraindications to using metformin, including chronic kidney disease, recent myocardial infarction, sepsis, acute kidney injury, severe dehydration, and alcohol abuse. Additionally, metformin should be discontinued before and after procedures involving iodine-containing x-ray contrast media to reduce the risk of contrast nephropathy.

When starting metformin, it is important to titrate the dose slowly to reduce the incidence of gastrointestinal side effects. If patients experience intolerable side effects, modified-release metformin may be considered as an alternative.

If a patient is experiencing metabolic ketoacidosis with normal or low glucose levels, alcohol consumption should be considered as a possible cause. This condition is characterized by partial respiratory compensation. While diabetic ketoacidosis could also be a potential cause, a serum glucose level of 3mmol/L makes it less likely. Therefore, the patient is more likely to be suffering from alcoholic ketoacidosis. It is important to note that a hyperosmolar hyperglycemic state would present with high serum glucose levels and normal ketone levels, while a diabetic hypoglycemic episode would not typically result in elevated ketone levels or metabolic acidosis.

Alcoholic ketoacidosis is a type of ketoacidosis that occurs in individuals who consume large amounts of alcohol regularly. This condition is not related to diabetes and is characterized by normal blood sugar levels. Alcoholics often suffer from malnutrition due to their irregular eating habits and may vomit the food they consume, leading to starvation. When the body becomes malnourished, it starts breaking down body fat, which produces ketones and leads to ketoacidosis.

The typical symptoms of alcoholic ketoacidosis include metabolic acidosis, elevated anion gap, elevated serum ketone levels, and normal or low glucose concentration. The most effective treatment for this condition is an infusion of saline and thiamine. Thiamine is essential to prevent the development of Wernicke encephalopathy or Korsakoff psychosis. Therefore, it is crucial to provide timely and appropriate treatment to individuals suffering from alcoholic ketoacidosis to prevent further complications.

Types of Vaccines and Their Definitions

Live Attenuated Vaccine:
This type of vaccine involves injecting a small sample of the virus into the body, allowing the immune system to fight it and create an immune response against it for future attacks. The MMR vaccine is an example of a live attenuated vaccine.

Conjugate Vaccine:
Conjugate vaccines are created by combining a weak antigen with a strong antigen to produce a stronger immune response. Typically, a polysaccharide is joined with a strong protein to create this type of vaccine.

Inactivated Vaccine:
Inactivated vaccines, such as the pertussis and hepatitis A vaccines, contain dead pathogens that cannot cause disease but still stimulate an immune response.

Subunit Vaccine:
Subunit vaccines only contain the antigenic component of the pathogen. However, there is no guarantee that immunological memory will be achieved appropriately. The pneumococcal vaccine is an example of a subunit vaccine.

Toxoid Vaccine:
Toxoid vaccines are toxins that have been deactivated but still stimulate an immune response from the immune system. Examples include the diphtheria and tetanus vaccines.

Understanding the Different Types of Vaccines

The most frequent bacterial organism responsible for infective exacerbations of COPD is Haemophilus influenzae. This patient’s symptoms of dyspnoea, productive cough, and wheeze on a background of known COPD indicate an infective exacerbation. Nebulisers may be added to the treatment plan if the patient is significantly wheezy. Legionella pneumophila is not a common cause of COPD exacerbation, as it typically causes atypical pneumonia with desaturation on exertion and hyponatraemia. Moraxella catarrhalis is another organism that can cause infective exacerbations of COPD, but it is less common than Haemophilus influenzae. Staphylococcus aureus is the most common cause of pneumonia following influenza infection and can sometimes cause infective exacerbations of COPD, but it is not as common as Haemophilus influenzae.

Acute exacerbations of COPD are a common reason for hospital visits in developed countries. The most common causes of these exacerbations are bacterial infections, with Haemophilus influenzae being the most common culprit, followed by Streptococcus pneumoniae and Moraxella catarrhalis. Respiratory viruses also account for around 30% of exacerbations, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators such as salbutamol and ipratropium should also be administered, along with steroid therapy. IV hydrocortisone may be considered instead of oral prednisolone, and IV theophylline may be used for patients not responding to nebulized bronchodilators. Non-invasive ventilation may be used for patients with type 2 respiratory failure, with bilevel positive airway pressure being the typical method used.

The appearance of a scaphoid abdomen is a common presentation of congenital diaphragmatic hernia, which occurs when abdominal contents protrude into the chest cavity. This condition can cause breathing difficulties and rapid breathing in newborns. The characteristic auscultation findings are caused by underdeveloped lungs and compression due to the presence of abdominal organs in the chest. Immediate medical attention and respiratory support are necessary. It is important to note that this specific concave abdominal appearance is not seen in any other conditions mentioned.

Understanding Congenital Diaphragmatic Hernia

Congenital diaphragmatic hernia (CDH) is a rare condition that affects approximately 1 in 2,000 newborns. It occurs when the diaphragm, a muscle that separates the chest and abdominal cavities, fails to form completely during fetal development. As a result, abdominal organs can move into the chest cavity, which can lead to underdeveloped lungs and high blood pressure in the lungs. This can cause respiratory distress shortly after birth.

The most common type of CDH is a left-sided posterolateral Bochdalek hernia, which accounts for about 85% of cases. This type of hernia occurs when the pleuroperitoneal canal, a structure that connects the chest and abdominal cavities during fetal development, fails to close properly.

Despite advances in medical treatment, only about 50% of newborns with CDH survive. Early diagnosis and prompt treatment are crucial for improving outcomes. Treatment may involve surgery to repair the diaphragm and move the abdominal organs back into their proper position. In some cases, a ventilator or extracorporeal membrane oxygenation (ECMO) may be necessary to support breathing until the lungs can function properly. Ongoing care and monitoring are also important to manage any long-term complications that may arise.

NICE guidelines recommend smoking cessation advice, annual influenza and one-off pneumococcal vaccinations, and pulmonary rehabilitation for COPD patients. Bronchodilator therapy is first-line treatment, with the addition of LABA and LAMA for patients without asthmatic features and LABA, ICS, and LAMA for those with asthmatic features. Theophylline is recommended after trials of bronchodilators or for patients who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients. Mucolytics should be considered for patients with a chronic productive cough. Loop diuretics and long-term oxygen therapy may be used for cor pulmonale. Smoking cessation and long-term oxygen therapy may improve survival in stable COPD patients. Lung volume reduction surgery may be considered in selected patients.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

Lithium is known to cause tremors, particularly a fine non-distractible rest tremor. This side effect is more common at higher doses and in cases of toxicity, but can still occur at treatment levels. Diazepam, a medication commonly used to manage acute anxiety and tremors, is unlikely to produce any motor effects from typical use. Mirtazapine, an antidepressant, can cause tremors but it is much less common than in other antidepressants. Olanzapine, an antipsychotic medication, can also cause tremors but they are usually coarse and affect the mouth and face. Based on the description of the tremor, it is more likely that lithium is the cause.

Lithium is a medication used to stabilize mood in individuals with bipolar disorder and as an adjunct in treatment-resistant depression. It has a narrow therapeutic range of 0.4-1.0 mmol/L and is primarily excreted by the kidneys. The mechanism of action is not fully understood, but it is believed to interfere with inositol triphosphate and cAMP formation. Adverse effects may include nausea, vomiting, diarrhea, fine tremors, nephrotoxicity, thyroid enlargement, ECG changes, weight gain, idiopathic intracranial hypertension, leucocytosis, hyperparathyroidism, and hypercalcemia.

Monitoring of patients taking lithium is crucial to prevent adverse effects and ensure therapeutic levels. It is recommended to check lithium levels 12 hours after the last dose and weekly after starting or changing the dose until levels are stable. Once established, lithium levels should be checked every three months. Thyroid and renal function should be monitored every six months. Patients should be provided with an information booklet, alert card, and record book to ensure proper management of their medication. Inadequate monitoring of patients taking lithium is common, and guidelines have been issued to address this issue.

Medications for Post-Myocardial Infarction Patients

Post-myocardial infarction (MI) patients require specific medications to prevent further cardiovascular disease and improve their overall health. One of the most important drugs to offer is a beta-blocker, such as bisoprolol, as soon as the patient is stable. This medication should be continued for at least 12 months after an MI in patients without left ventricular systolic dysfunction or heart failure, and indefinitely in those with left ventricular systolic dysfunction. While beta-blockers can reduce mortality and morbidity for up to a year after an MI, recent studies suggest that continuing treatment beyond a year may not provide any additional benefits. Other medications, such as amiodarone, isosorbide mononitrate, and nicorandil, offer symptom relief but do not reduce mortality or morbidity. Calcium-channel blockers, like diltiazem, may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction if beta-blockers are contraindicated or discontinued. However, current guidelines recommend offering all post-MI patients an ACE inhibitor, dual antiplatelet therapy, beta-blocker, and statin to improve their long-term health outcomes.

For patients with bradycardia and signs of shock, the immediate treatment is 500 micrograms of atropine, which can be repeated up to a maximum of 3mg. This is in line with the Resuscitation Council Guidelines. It is important to identify the cause of the bradycardia and check for reversible causes, while also managing the bradycardia to prevent further deterioration and possible cardiac arrest.

It should be noted that 3mg of atropine is the maximum amount that can be given, not the starting dose. If there is an insufficient response to 500 micrograms of atropine, further doses can be given until a total of 3mg has been administered.

Administering 500ml of intravenous fluid stat may temporarily increase cardiac output, but it will not treat the bradycardia causing the patient’s shock.

Transcutaneous pacing is a method of temporarily pacing the heart in an emergency by delivering pulses of electric current through the chest. It may be used as an interim measure if treatment with atropine is unsuccessful, while awaiting the establishment of more permanent measures such as transvenous pacing or permanent pacemaker insertion.

Management of Bradycardia in Peri-Arrest Rhythms

The 2015 Resuscitation Council (UK) guidelines highlight the importance of identifying adverse signs and potential risk of asystole in the management of bradycardia in peri-arrest rhythms. Adverse signs indicating haemodynamic compromise include shock, syncope, myocardial ischaemia, and heart failure. Atropine (500 mcg IV) is the first line treatment in this situation. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, and isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Furthermore, the presence of risk factors for asystole such as complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, and ventricular pause > 3 seconds should be considered. Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing. Effective management of bradycardia in peri-arrest rhythms is crucial in preventing further deterioration and improving patient outcomes.

Acute angle closure glaucoma is identified by symptoms such as eye pain, reduced visual clarity, aggravation with mydriasis (e.g. in a dark cinema), and haloes around lights. It may also cause a general feeling of illness. Migraine with aura is an unlikely diagnosis as it does not involve eye pain. Sudden painless loss of vision is a symptom of vitreous haemorrhage. While optic neuritis can cause eye pain, it typically does not worsen with mydriasis.

Glaucoma is a group of disorders that cause optic neuropathy due to increased intraocular pressure (IOP). However, not all patients with raised IOP have glaucoma, and vice versa. Acute angle-closure glaucoma (AACG) is a type of glaucoma where there is a rise in IOP due to impaired aqueous outflow. Factors that increase the risk of AACG include hypermetropia, pupillary dilatation, and lens growth associated with age. Symptoms of AACG include severe pain, decreased visual acuity, haloes around lights, and a hard, red-eye. Management of AACG is an emergency and requires urgent referral to an ophthalmologist. Emergency medical treatment is necessary to lower the IOP, followed by definitive surgical treatment once the acute attack has subsided.

There are no specific guidelines for the initial medical treatment of AACG, but a combination of eye drops may be used, including a direct parasympathomimetic, a beta-blocker, and an alpha-2 agonist. Intravenous acetazolamide may also be administered to reduce aqueous secretions. Definitive management of AACG involves laser peripheral iridotomy, which creates a small hole in the peripheral iris to allow aqueous humour to flow to the angle. It is important to seek medical attention immediately if symptoms of AACG are present to prevent permanent vision loss.

Detecting warfarin over anticoagulation can be crucial, and subconjunctival haemorrhage may serve as an early indicator. If a patient experiences non-traumatic subconjunctival haemorrhage, it is important to check their INR level before proceeding with any other treatment. Urgent ophthalmology review is unnecessary if the patient’s vision is unaffected. If the INR level is normal, the patient can be reassured that the condition will resolve on its own within a few weeks. Topical lubricants may be prescribed to alleviate any irritation caused by the subconjunctival haemorrhage. A skull x-ray is not necessary in this case as there is no history of trauma.

Understanding Subconjunctival Haemorrhage

Subconjunctival haemorrhage occurs when blood vessels bleed into the subconjunctival space, usually those that supply the conjunctiva or episclera. Trauma is the most common cause, followed by spontaneous idiopathic cases, Valsalva manoeuvres, and several systemic diseases. Although subconjunctival haemorrhages can look alarming, they are rarely an indicator of anything sinister.

Subconjunctival haemorrhages are more common in women than in men when there has been no history of trauma. The annual incidence of non-traumatic subconjunctival haemorrhages is 0.6%, and the risk increases with age as the risk factors are more common in elderly patients. Newborns are also more susceptible. The incidence of both traumatic and non-traumatic subconjunctival haemorrhages is 2.6%.

The most common causes of subconjunctival haemorrhages are trauma and contact lens usage, which are often the sole risk factor in younger patients. Other risk factors include idiopathic causes, Valsalva manoeuvre, hypertension, bleeding disorders, drugs such as aspirin, NSAIDs and anticoagulants, diabetes, arterial disease, and hyperlipidaemia.

Subconjunctival haemorrhages are mostly asymptomatic, but patients may experience mild irritation. The main sign is a flat, red patch on the conjunctiva with well-defined edges and normal conjunctiva surrounding it. Traumatic haemorrhages are most common in the temporal region, with the inferior conjunctiva as the next most commonly affected area. Vision should be normal, including acuity, visual fields, and range of eye movements. On examination, the fundus should be normal.

The diagnosis of a subconjunctival haemorrhage is a clinical one. If there is no obvious traumatic cause, check the patient’s blood pressure. If raised, refer the patient appropriately. If the patient is taking warfarin, check the INR. If raised, refer for appropriate adjustments to the dose to bring the INR back into the target range. Recurrent or spontaneous, bilateral subconjunctival haemorrhages warrant investigations for bleeding disorders or other pathology.

Reassure the patient that subconjunctival haemorrhage is a benign condition that will resolve on its own in 2 to

As the woman is experiencing symptoms, she requires treatment with a pregnancy-safe antibiotic. Trimethoprim is not recommended for use during the first trimester of pregnancy, making nitrofurantoin the appropriate choice. According to NICE CKS, amoxicillin should not be used due to its high resistance levels.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. The management of UTIs depends on various factors such as the patient’s age, gender, and pregnancy status. For non-pregnant women, local antibiotic guidelines should be followed if available. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. However, if the patient is aged over 65 years or has visible or non-visible haematuria, a urine culture should be sent. Pregnant women with UTIs should be treated with nitrofurantoin, amoxicillin, or cefalexin for seven days. Trimethoprim should be avoided during pregnancy as it is teratogenic in the first trimester. Asymptomatic bacteriuria in pregnant women should also be treated to prevent progression to acute pyelonephritis. Men with UTIs should be offered a seven-day course of trimethoprim or nitrofurantoin unless prostatitis is suspected. A urine culture should be sent before antibiotics are started. Catheterised patients should not be treated for asymptomatic bacteria, but if symptomatic, a seven-day course of antibiotics should be given. Acute pyelonephritis requires hospital admission and treatment with a broad-spectrum cephalosporin or quinolone for 10-14 days. Referral to urology is not routinely required for men who have had one uncomplicated lower UTI.

Patients with symptoms of pulmonary embolism, such as chest pain and shortness of breath, are typically treated for 3 months if the PE is provoked. This is especially true for patients who have had recent surgery, as they are at a higher risk for a provoked PE. Clinical signs of a PE include tachycardia, hypoxia, and an elevated D-dimer. ECG changes may include sinus tachycardia, S1Q3T3, and T-wave inversion in the right-sided leads. Patients with right heart strain may also have raised troponin levels. The treatment of choice for a provoked PE is a low-molecular-weight heparin or a direct oral anticoagulant. Apixaban for 6 months is used for unprovoked PEs without risk factors, while apixaban for 12 months is not routinely prescribed. Dual antiplatelet therapy is used for coronary ischaemia, but a raised D-dimer, hypoxia, and ECG changes suggest a PE is more likely.

Management of Pulmonary Embolism: NICE Guidelines

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management, and the guidelines recommend using apixaban or rivaroxaban as the first-line treatment following the diagnosis of a PE. If neither of these is suitable, LMWH followed by dabigatran or edoxaban or LMWH followed by a vitamin K antagonist (VKA) can be used. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation is determined by whether the VTE was provoked or unprovoked, with treatment typically stopped after 3-6 months for provoked VTE and continued for up to 6 months for unprovoked VTE.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak.

Overall, the updated NICE guidelines provide clear recommendations for the management of PE, including the use of DOACs as first-line treatment and outpatient management for low-risk patients. The guidelines also emphasize the importance of individualized treatment based on risk stratification and balancing the risks of VTE recurrence and bleeding.

Cardiac Abnormalities Associated with Marfan Syndrome

Marfan syndrome is commonly associated with cardiac abnormalities, with aortic root dilatation being the most prevalent, found in approximately 80% of cases. This can lead to aortic regurgitation and even dissection. While there is some evidence of a slight increase in atrial septal defects in Marfan syndrome patients, it is not as common as aortic regurgitation or mitral valve prolapse. Dilated cardiomyopathy can also present in Marfan syndrome patients, although it is not as prevalent as aortic root dilatation or regurgitation. Pulmonary regurgitation is also increased in incidence in Marfan syndrome, but it is still less common than aortic regurgitation. Finally, while persistent ductus arteriosus is more commonly found in Marfan syndrome patients than in the general population, the association is relatively weak. Overall, Marfan syndrome patients should be monitored closely for these cardiac abnormalities to ensure proper management and treatment.

Symptoms and Complications of Thyroidectomy

Thyroidectomy is a common surgical procedure that involves the removal of the thyroid gland. However, it can lead to various complications, including hypoparathyroidism and hyperparathyroidism. Here are some symptoms to watch out for:

Acute hypocalcaemia, characterized by tingling around the hands, feet, or mouth, and unusual muscle movements, is a common complication of hypoparathyroidism post-thyroidectomy. Intravenous calcium may be necessary to correct the hypocalcaemia.

Headache, sweating, and tachycardia are classic symptoms of phaeochromocytoma, which can occur in patients at risk of hypoparathyroidism post-thyroidectomy.

Dry, thick skin, coarse hair, and brittle nails are signs of hypothyroidism, not hypoparathyroidism.

Feeling thirsty and passing a lot of urine are signs of hypercalcaemia, which may be caused by hyperparathyroidism. Hypoparathyroidism post-thyroidectomy is a common complication that can lead to hypercalcaemia.

Hyperactivity and mood swings are more indicative of hyperthyroidism, but patients at risk of hypoparathyroidism post-thyroidectomy should still be monitored for these symptoms.

In summary, patients who undergo thyroidectomy should be aware of the potential complications and symptoms that may arise. Regular monitoring and prompt medical attention can help manage these issues effectively.

Acromegaly is a condition caused by excessive secretion of growth hormone from an anterior pituitary tumor, resulting in enlarged hands, feet, and jaw, as well as other symptoms. While surgery is the preferred treatment, somatostatin analogues such as octreotide and lanreotide can be used if surgery fails. Somatostatin is an inhibitory hormone that can suppress growth hormone release. However, it can also cause side effects such as bradycardia, hypothyroidism, and hypoglycemia. Cushing’s disease, caused by excess adrenocorticotropic hormone, can be treated with pituitary gland removal, radiotherapy, or cortisol-inhibiting medications. Conn syndrome, or primary aldosteronism, is usually treated with surgery. Type I diabetes is treated with insulin, while Type II diabetes is treated with insulin and oral hypoglycemic agents. Parathyroid adenomas are also treated surgically.

Palmoplantar pustulosis is often accompanied by psoriasis on other areas of the body and is strongly linked to smoking. Unlike pompholyx eczema, the connection to high temperatures and humidity is not as significant. Scabies, which is caused by the parasite Sarcoptes scabiei, results in severe itching of the hands and web spaces but is typically not a recurring issue. Symptoms include linear burrows and erythematous papules rather than vesicles.

Understanding Pompholyx Eczema

Pompholyx eczema, also known as dyshidrotic eczema, is a type of skin condition that affects both the hands and feet. It is often triggered by high temperatures and humidity, such as sweating. The main symptom of pompholyx eczema is the appearance of small blisters on the palms and soles, which can be intensely itchy and sometimes accompanied by a burning sensation. Once the blisters burst, the skin may become dry and crack.

To manage pompholyx eczema, cool compresses and emollients can be used to soothe the affected areas. Topical steroids may also be prescribed to reduce inflammation and itching. It is important to avoid further irritation by wearing gloves or protective footwear and avoiding exposure to irritants. With proper management, the symptoms of pompholyx eczema can be controlled and minimized.

Men with BRCA2 mutation are at a higher risk of developing prostate cancer, while both men and women with this mutation have a significantly increased risk of developing breast cancer. Additionally, women with BRCA2 mutation are more likely to develop ovarian cancer. Although young-onset colorectal cancer is linked to BRCA1 mutation, there is no such association observed in individuals with BRCA2 mutation.

Li-Fraumeni Syndrome is caused by mutations in the p53 gene and increases the risk of developing sarcomas and leukemias. BRCA 1 and 2 mutations increase the risk of breast and ovarian cancer, and BRCA 2 is also associated with prostate cancer in men. Lynch Syndrome increases the risk of colon and endometrial cancer, and can be identified using the Amsterdam criteria. Gardner’s Syndrome is a familial colorectal polyposis that can lead to colectomy to reduce the risk of colorectal cancer.

After losing weight, the recommended initial treatment for moderate/severe obstructive sleep apnoea is CPAP.

CPAP is the most widely used treatment for obstructive sleep apnoea (OSA) and is effective for both moderate and severe cases. However, lifestyle changes such as weight loss, quitting smoking, and avoiding alcohol should be attempted first. Although oral appliances can be used, they are not as effective as CPAP. Surgical treatments for OSA are not the first choice and have limited evidence.

Understanding Obstructive Sleep Apnoea/Hypopnoea Syndrome

Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a condition where the upper airway becomes partially or completely blocked during sleep, leading to interrupted breathing and reduced oxygen levels in the body. There are several predisposing factors for OSAHS, including obesity, macroglossia, large tonsils, and Marfan’s syndrome. The condition is often characterized by excessive snoring and periods of apnoea, which can be reported by the patient’s partner.

OSAHS can have several consequences, including daytime somnolence, compensated respiratory acidosis, and hypertension. To assess sleepiness, healthcare professionals may use tools such as the Epworth Sleepiness Scale or the Multiple Sleep Latency Test. Diagnostic tests for OSAHS include sleep studies, ranging from monitoring pulse oximetry to full polysomnography.

Management of OSAHS typically involves weight loss and continuous positive airway pressure (CPAP) as the first line of treatment for moderate or severe cases. Intra-oral devices may be used if CPAP is not tolerated or for patients with mild OSAHS. It is important to inform the DVLA if OSAHS is causing excessive daytime sleepiness. While there is limited evidence to support the use of pharmacological agents, healthcare professionals may consider them in certain cases.

Overall, understanding OSAHS and its management is crucial for improving the quality of life for patients with this condition.

Common Sites of Metastatic Spread in Bone

Metastatic spread to the bone is a common occurrence in many types of cancer. The following are some of the most common sites of metastases in bone:

Spine: The spine is the most common site for bony metastases, with spread often found from a range of solid and haematological cancers, as well as infectious diseases such as tuberculosis.

Ribs: While breast cancer is known to spread to the ribs, this is not the case for many other cancers.

Pelvis: The pelvis is a prevalent site of metastatic spread occurring mostly from the prostate, breast, kidney, lung, and thyroid cancer.

Skull: Skull metastases are seen in 15-25% of all cancer patients and tend to include those from the breast, lungs, prostate, and thyroid, as well as melanoma.

Long bones: Localised bone pain is a red flag for metastatic spread to any of the long bones such as the femur and humerus. Breast, prostate, renal, thyroid, and lung cancers frequently metastasize to these areas.

Overall, understanding the common sites of metastatic spread in bone can help with early detection and treatment of cancer.

If the COC is not started on the first day of the next period, it is important to follow the standard guidelines and use condoms for 7 days.

Special Situations for Combined Oral Contraceptive Pill

Concurrent antibiotic use has been a concern for many years in the UK, as doctors have advised that it may interfere with the effectiveness of the combined oral contraceptive pill. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines to abandon the extra precautions previously advised during antibiotic treatment and for 7 days afterwards. The latest edition of the British National Formulary (BNF) has also been updated to reflect this guidance, although precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

When it comes to switching combined oral contraceptive pills, the BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice. The FSRH’s Combined Oral Contraception guidelines state that the pill-free interval does not need to be omitted, while the BNF advises missing the pill-free interval if the progesterone changes. Given this uncertainty, it is best to follow the BNF’s advice.

When evaluating a patient with back pain, it is crucial to be aware of red flag symptoms such as thoracic back pain, unexplained weight loss, local spinal tenderness, focal neurology, and age over 50 or under 18. Thoracic back pain is particularly concerning for malignancy in patients over 50 years old. Additionally, if symptoms have a gradual onset and do not improve with pain relief, further investigation is necessary. Gender and smoking history are not considered red flag risk factors for back pain.

Lower back pain is a common issue that is often caused by muscular strain. However, it is important to be aware of potential underlying causes that may require specific treatment. Certain red flags should be considered, such as age under 20 or over 50, a history of cancer, night pain, trauma, or systemic illness. There are also specific causes of lower back pain that should be kept in mind. Facet joint pain may be acute or chronic, worse in the morning and on standing, and typically worsens with back extension. Spinal stenosis may cause leg pain, numbness, and weakness that is worse on walking and relieved by sitting or leaning forward. Ankylosing spondylitis is more common in young men and causes stiffness that is worse in the morning and improves with activity. Peripheral arterial disease may cause pain on walking and weak foot pulses. It is important to consider these potential causes and seek appropriate diagnosis and treatment.

Methotrexate has the potential to cause pneumonitis, which is characterized by symptoms such as cough, fever, and difficulty breathing. Failure to promptly identify and treat pneumonitis can result in permanent lung damage. Therefore, the British National Formulary advises patients to seek medical attention if they experience any of these symptoms, and physicians should monitor for signs of pneumonitis during each visit and discontinue the medication if it is suspected. It should be noted that acute respiratory distress syndrome is not a known side effect of methotrexate.

Methotrexate: An Antimetabolite with Potentially Life-Threatening Side Effects

Methotrexate is an antimetabolite drug that inhibits the enzyme dihydrofolate reductase, which is essential for the synthesis of purines and pyrimidines. It is commonly used to treat inflammatory arthritis, psoriasis, and some types of leukemia. However, it is considered an important drug due to its potential for life-threatening side effects. Careful prescribing and close monitoring are essential to ensure patient safety.

The adverse effects of methotrexate include mucositis, myelosuppression, pneumonitis, pulmonary fibrosis, and liver fibrosis. The most common pulmonary manifestation is pneumonitis, which typically develops within a year of starting treatment and presents with non-productive cough, dyspnea, malaise, and fever. Women should avoid pregnancy for at least 6 months after treatment has stopped, and men using methotrexate need to use effective contraception for at least 6 months after treatment.

When prescribing methotrexate, it is important to follow guidelines and monitor patients regularly. Methotrexate is taken weekly, and FBC, U&E, and LFTs need to be regularly monitored. The starting dose is 7.5 mg weekly, and folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after the methotrexate dose. Only one strength of methotrexate tablet should be prescribed, usually 2.5 mg. It is also important to avoid prescribing trimethoprim or co-trimoxazole concurrently, as it increases the risk of marrow aplasia, and high-dose aspirin increases the risk of methotrexate toxicity.

In case of methotrexate toxicity, the treatment of choice is folinic acid. Methotrexate is a drug with a high potential for patient harm, and it is crucial to be familiar with guidelines relating to its use to ensure patient safety.

Carcinoid tumors can lead to an increase in urinary 5-HIAA due to the release of serotonin. Symptoms of carcinoid syndrome include flushing, diarrhea, bronchospasm, hypotension, and weight loss. The appropriate diagnostic test for this condition is a urinary 5-HIAA test. CA125 is not relevant in this case as it is used to detect ovarian cancer. MRCP is used to investigate gallbladder or pancreatic conditions, while urinary metanephrines are used to diagnose phaeochromocytoma.

Carcinoid Tumours and Syndrome

Carcinoid tumours are a type of neuroendocrine tumour that can secrete various hormones and bioactive substances, including serotonin. When these tumours metastasize to the liver, they can release serotonin into the systemic circulation, leading to a condition known as carcinoid syndrome. This syndrome can also occur with lung carcinoids, as the mediators are not cleared by the liver.

The earliest symptom of carcinoid syndrome is often flushing, followed by diarrhoea, bronchospasm, hypotension, and right heart valvular stenosis. In bronchial carcinoids, the left heart can also be affected. In some cases, other molecules such as ACTH and GHRH may be secreted, resulting in conditions like Cushing’s syndrome. Pellagra, a condition caused by a deficiency of niacin, can also develop as dietary tryptophan is diverted to serotonin by the tumour.

To diagnose carcinoid syndrome, doctors may perform a urinary 5-HIAA test or measure plasma chromogranin A levels. Treatment typically involves somatostatin analogues like octreotide to manage symptoms, while cyproheptadine may help with diarrhoea. Proper management of carcinoid tumours and syndrome is crucial to prevent complications and improve quality of life for patients.